Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1461-1471

  Kondo, Eisaku ^a   Tanaka, Takehiro ^a   Miyake, Takayoshi ^a   Ichikawa, Tomotsugu ^a   Hirai, Masahiko ^c   Adachi, Masaki ^c   Yoshikawa, Kazuhiro ^d   Ichimura, Koichi ^a   Ohara, Nobuya ^a   Moriwaki, Akiyoshi ^b   Date, Isao ^a   Ueda, Ryuzo ^e   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Chugoku Gakuen University   (Japan)

^c RandD Division   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ANTINEOPLASTIC AGENT; PEPTIDE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49849085428     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2010     Document Type: Article

References (37)

1. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;392:806-11.
2. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
3. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach totrea ting cancer. Nature 2004;4:956-65.
4. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer. J Clin Oncol 2005;23:2556-68.
5. Mellinghoff IK, Wang M, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Eng J Med 2005;353:2012-24.
6. Newcomb EW, Alonso M, Sung T, et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol 2000;31:115-9.
7. Simon M, Koster G, Menon AG, Schramm J. Functional evidence for a role of combined CDKN2A (p16-14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol (Berl) 1999;98:444-52.
8. Saxena A, Shriml LM, Dean M, Ali IU. Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences. Oncogene 1999;18:1385-90.
9. Adachi Y, Chandrasekar N, Kin Y, et al. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 2002;21:87-95.
10. Labuhn M, Jones G, Speel EJ, et al. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene 2001;20:1103-9.
11. Kondo E, Seto M, Yoshikawa K, Yoshino T. Highly efficient delivery of p16 anti-tumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 2004;3:1623-30.
12. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001;19:1173-6.
13. Fahraeus R, Lain S, Ball KL, Lane DP. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 1998;16:587-96.
14. Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res 2002;60:257-70.
15. Kontopidis G, Andrews MJ, McInnes C, Cowan A, Powers H, Innes L. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure 2003;11:1537-46.
16. DiGiammarino EL, Filippov I, Weber JD, Bothner B, Kriwacki RW. Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein. Biochemistry 2001;40:2379-86.
17. Abe T, Terada K, Wakimoto H, et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res 2003;63:2300-5.
18. Abe T, Wakimoto H, Bookstein R, et al. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther 2002;9:228-35.
19. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 2002;100:43-8.
20. Fink JR, LeBien TW. Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. Exp Hematol 2001;29:490-8.
21. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003;161:653-60.
22. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
23. Meinhardt G, Roth J, Hass R. Activation of protein kinase C relays distinct signaling pathways in the same cell type: differentiation and caspase-mediated apoptosis. Cell Death Differ 2000;7:795-803.
24. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
25. Perez F, Joliot A, Bloch-Gallego E, Zahraoui A, Triller A, Prochiantz A. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J Cell Sci 1992;102:717-22.
26. Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
27. Adams J. Proteasome inhibition in cancer: development of PS341. Semin Oncol 2001;28:613-9.
28. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
29. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-34.
30. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
31. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
32. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997;3:313-9.
33. Kim SK, Wang KC, Cho BK, et al. Interaction between p53 and p16 expressed by adenoviral vectors in human malignant glioma cell lines. J Neurosurg 2002;97:143-50.
34. Cao G, Pei W, Ge H, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002;22:5423-31.
35. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:E36. Epub 2004 Feb 17.
36. Hiromura M, Okada F, Obata T, et al. Inhibition of Akt kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1. J Biol Chem 2004;279:53407-18.
37. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001;61:7709-12.